MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-1976 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 24/November/2016, 3.33 pm

Natural product-derived combo therapy for ACAT1-overexpressing Human cancers: Curcumin and (6)-gingerol (6G) combo, one of the main components of Turmeric and Ginger, respectively, inhibits Mitochondrial acetyl-CoA acetyltransferase 1 (ACAT1) expression, acetylation of Pyruvate dehydrogenase (PDH) and PDH phosphatase, pyruvate dehydrogenase complex (PDC) formation and tumor growth via down regulation of its target gene, 24/November/2015, 2.57 pm
November 24, 2016
Anti-metastasis therapy: MiRNA-9600 increases the expression of metastasis suppressor Sprouty2 and inhibits proliferation, invasion and metastasis of cancer cells via down regulation of its target gene,24/November/2015, 3.38 pm
November 24, 2016
Show all

Introduction:What they say

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.


What we say

price-300

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-1976 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.


Research Findings

This study suggests a natural product-based Human cancer therapy.

The study presented here suggests that MiR-1976, by increasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment anti-tumor activity of the immune system; & (3) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing MiR-1976 activators may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with factual evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300

Undisclosed information: How MiR-1976 suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation


References:

Citation: Boominathan, L., MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-1976 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 24/November/2016, 3.33 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.